Harbour Investments’s TG Therapeutics TGTX Stock Holding History

Harbour Investments’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.6K	Buy	485 +31	+7%	+$1.27K	﹤0.01%	2785
2026 Q1	$15.1K	Hold	454	–	–	﹤0.01%	3047
2025 Q4	$13.5K	Buy	+454	New	+$14.8K	﹤0.01%	2600
2025 Q2	–	Sell	-149	Closed	-$5.88K	–	3716
2025 Q1	$5.88K	Hold	149	–	–	﹤0.01%	2763
2024 Q4	$4.49K	Hold	149	–	–	﹤0.01%	2768
2024 Q3	$3.48K	Hold	149	–	–	﹤0.01%	2745
2024 Q2	$2.65K	Buy	+149	New	+$2.38K	﹤0.01%	2726
2021 Q4	–	Sell	-28	Closed	-$1K	–	3595
2021 Q3	$1K	Sell	28 -1,069	-97%	-$33.1K	﹤0.01%	3598
2021 Q2	$43K	Buy	1,097 +1,070	+3,963%	+$42K	﹤0.01%	1911
2021 Q1	$1K	Buy	+27	New	+$1.3K	﹤0.01%	3488

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Harbour Investments's TGTX Position: Q2 2026 in Review

Harbour Investments increased its TG Therapeutics (TGTX) stake by 6.8% in Q2 2026, buying an estimated $1.27K and bringing the position to 485 shares worth $26.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2785.

Harbour Investments first reported a position in TGTX in Q1 2021 and has held it in 10 quarters since. The position peaked at $43K in Q2 2021. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Harbour Investments held 485 shares of TG Therapeutics worth $26.6K as of Q2 2026.
Harbour Investments bought 31 TG Therapeutics shares in Q2 2026, an estimated $1.27K.
TG Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #2785 holding.
Harbour Investments first reported a position in TG Therapeutics in Q1 2021 and has held it in 10 quarters since.
Harbour Investments's TG Therapeutics position peaked at $43K in Q2 2021.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.